Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span.
Excellent balance sheet and overvalued.
Share Price & News
How has Unity Biotechnology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UBX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: UBX underperformed the US Biotechs industry which returned 1.8% over the past year.
Return vs Market: UBX underperformed the US Market which returned -10.4% over the past year.
Price Volatility Vs. Market
How volatile is Unity Biotechnology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StImagine Owning Unity Biotechnology (NASDAQ:UBX) And Wondering If The 43% Share Price Slide Is Justified
2 months ago | Simply Wall StWe Think Unity Biotechnology (NASDAQ:UBX) Needs To Drive Business Growth Carefully
3 months ago | Simply Wall StCan We See Significant Insider Ownership On The Unity Biotechnology, Inc. (NASDAQ:UBX) Share Register?
Is Unity Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate UBX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate UBX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: UBX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: UBX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UBX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UBX is good value based on its PB Ratio (2.3x) compared to the US Biotechs industry average (2.6x).
How is Unity Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if UBX's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if UBX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if UBX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if UBX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UBX is forecast to be unprofitable in 3 years.
How has Unity Biotechnology performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: UBX is currently unprofitable.
Growing Profit Margin: UBX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if UBX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare UBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: UBX has a negative Return on Equity (-68.08%), as it is currently unprofitable.
How is Unity Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: UBX's short term assets ($129.5M) exceed its short term liabilities ($17.2M).
Long Term Liabilities: UBX's short term assets ($129.5M) exceed its long term liabilities ($13.3M).
Debt to Equity History and Analysis
Debt Level: UBX is debt free.
Reducing Debt: UBX has not had any debt for past 5 years.
Inventory Level: UBX has a low level of unsold assets or inventory.
Debt Coverage by Assets: UBX's debt is not covered by short term assets (assets are -18498.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UBX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if UBX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Unity Biotechnology's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate UBX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UBX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UBX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Anirvan Ghosh, Ph.D. serves as Chief Executive Officer of Unity Biotechnology, Inc. since March 20, 2020. Dr. Ghosh had been Senior Vice President of Research and Early Development at Biogen Inc. since ...
|Chief Medical Officer||4.17yrs||US$951.85k||0.90% $2.6m|
|Chief Executive Officer||no data||no data||no data|
|9.17yrs||no data||no data|
|9.17yrs||no data||no data|
|9.17yrs||no data||no data|
|Chief Financial Officer||2.42yrs||US$1.29m||0.24% $674.3k|
|Senior Vice President of Operations||2.83yrs||no data||no data|
|Chief Scientific Officer||4.25yrs||no data||0.71% $2.0m|
|General Counsel & Corporate Secretary||2.67yrs||no data||0.044% $125.4k|
Experienced Management: UBX's management team is considered experienced (4.2 years average tenure).
|Independent Director||8.25yrs||no data||no data|
|Independent Director||5yrs||US$551.11k||0.021% $60.5k|
|Lead Independent Director||no data||US$933.01k||0.0069% $19.4k|
|Independent Director||8.25yrs||US$551.83k||0.24% $672.3k|
|Independent Director||2.83yrs||US$167.90k||0.18% $504.2k|
|Independent Director||2yrs||US$285.51k||no data|
|Independent Director||1.25yrs||US$533.51k||no data|
Experienced Board: UBX's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.3%.
Unity Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Unity Biotechnology, Inc.
- Ticker: UBX
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$283.298m
- Shares outstanding: 47.61m
- Website: https://www.unitybiotechnology.com
Number of Employees
- Unity Biotechnology, Inc.
- 3280 Bayshore Boulevard
- Suite 100
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UBX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 2018|
|9U9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2018|
|0YC0||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2018|
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 03:57|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.